Citius Oncology Inc (CTOR) Stock Price, Quote & News

Company Profile

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 908 967 6677

Address:

11 Commerce Drive, First Floor, Cranford, United States

SweStonk Mar. 18 at 6:20 PM

$CTXR well well, lymphir seem not to have been what u all expected. $CTOR sinking faster than titanic. ML = dead Halo = dead Lymphir was the last shot and sales are nowhere near what is needed. Dilution anyday to slow the sinking, but it is invetable at this point. Using shareholders money to buy lymphir and put the company in great debt was the most stupid thing management could do. Bankruptcy incoming and deerfield will scoop this up cheap and take it private. Shareholders get nothing.

0 · Reply

SweStonk Mar. 18 at 6:13 PM

$CTOR dropping faster than dogshit

0 · Reply

SweStonk Mar. 17 at 5:29 PM

$CTOR hmmm, where is the bottom 😬

0 · Reply

erichartmann Mar. 16 at 5:24 PM

$CTOR Yep! Lost 90K on CTXR. Both are a total scam. Lenny is simply a lying crook.. period

2 · Reply

SKEETER_1 Mar. 13 at 3:59 PM

$CTOR ouch! People starting to realize ctor is a scam company. Lymphir has no value. Theres a reason why no funds or banks touch this. 3.9m in sales they should have banks lined up to finance them. Because it probably cost 10 mil to pump 3 mil in sales expect this to go to zero fast. .40 by end of month 2026: Delays/Dilution/Delisting

1 · Reply

Jojackthewonderskunk Mar. 12 at 4:07 PM

$CTOR for the record all the trial data we just got was actually good news.

0 · Reply

SweStonk Mar. 10 at 6:27 PM

$CTOR Could you explain this @TwongStocks ? Same company, same filing date but different numbers?

2 · Reply

uebersoldat Mar. 10 at 1:40 PM

$CTOR I think this will fire off to the moon once they start actually getting revenue. I'm glad they're releasing positive news but as we all know - their financial runway is worrisome and dilution still looms. I'm bullish, but it's definitely a long bullish. Bearish in the near-term.

1 · Reply

SweStonk Mar. 10 at 1:31 PM

$CTOR tides changing? Need confirmation. But not bearish now. Neautral

0 · Reply

TwongStocks Mar. 10 at 1:09 PM

$CTOR Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers https://www.citiusonc.com/news/news-details/2026/Citius-Oncology-Announces-Positive-Topline-Results-from-InvestigatorInitiated-Phase-1-Study-of-LYMPHIR-in-Combination-with-Pembrolizumab-in-Relapsed-or-Refractory-Gynecologic-Cancers/default.aspx

0 · Reply

Market Cap	67.58M
Revenue (ttm)	0.00
Net Income (ttm)	-24.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.26

Volume	133,497
Avg Vol	289,292
Day's Range	N/A - N/A
Shares Out	88.28M
Stochastic %K	0%
Beta	3.03
Analysts	Strong Sell
Price Target	$6.00